48th week of 2021 patent applcation highlights part 11 |
Patent application number | Title | Published |
20210369666 | DEVICES AND METHODS FOR THE TREATMENT OF A ZOONOTIC HERPESVIRUS INFECTION - The present disclosure relates to tetrapodal zinc-oxide nanostructures (T-ZONS), microneedle devices, and methods for treating or preventing a zoonotic herpesvirus infection. | 2021-12-02 |
20210369667 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS, ECZEMA, BURNS, WOUNDS AND CERTAIN CANCERS - Novel polyphenol compositions and methods for the treatment and prevention of radiation dermatitis, eczema, thermal burns, wounds, and certain cancers. The disclosure also relates to methods for the preparation of polyphenol compositions including flavonoid compositions. | 2021-12-02 |
20210369668 | COMPOSITION EXHIBITING ENHANCED OXIDATIVE STABILITY - A composition comprising α-tocopherol acetate (also referred to as Vitamin E acetate “Vit E Acetate”) and docosahexaenoic acid ethyl ester (“DHA EE”), exhibits surprising oxidative stability. | 2021-12-02 |
20210369669 | AUTOPHAGY ACTIVATORS AND INHIBITORS OF FERROPTOSIS FOR PREVENTING ACUTE RENAL FAILURE AND NEUROTOXCITY INDUCED BY CERTAIN ANTIBIOTICS - The present disclosure relates to pharmaceutical compositions, pharmaceutical combinations and methods of treatment including zileuton, edaravone and atorvastatin compounds combined with nephrotoxicity-inducing antibiotic or anticancer drugs for treating bacterial infections and cancers. | 2021-12-02 |
20210369670 | USE OF SWELL1 INHIBITORS AND MODULATORS TO TREAT TYPE 2 DIABETES AND OBESITY - The invention provides the use of SWELL1 inhibitors and modulators for therapeutic use, e.g., to treat obesity and type 2 diabetes. | 2021-12-02 |
20210369671 | CORROLES FOR TREATING HUMAN CYTOMEGALOVIRUS INFECTIONS - Disclosed is a family of corroles for its use in the treatment of an infection by human herpesvirus, especially in the treatment of an infection by human cytomegalovirus. | 2021-12-02 |
20210369672 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE - The hemitartrate salt of a compound represented by the following structural formula: | 2021-12-02 |
20210369673 | Chlorthalidone Compositions And Methods - Compositions of a stabilized chlorthalidone suspension and methods for making a stabilized chlorthalidone suspension include chlorthalidone along with a solubilizing and/or wetting agent, a suspending agent, and a viscosity increasing agent and/or an anti-caking agent, wherein the stabilized chlorthalidone suspension is a uniform dispersion with consistent concentration of chlorthalidone throughout the composition and storage. | 2021-12-02 |
20210369674 | HEALTH MANAGEMENT COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - The nutraceutical composition includes a neuroprotecting composition, an anti-inflammatory composition, a cardiovascular protecting composition, an antioxidant composition, and a gelling component in a sufficient amount to provide a cohesive gelled product. | 2021-12-02 |
20210369675 | ANTIMICROBIAL DRUG METHODS OF USE & THERAPEUTIC COMPOSITIONS - This invention relates to the medical use of an antimicrobial agent, racemic Ornidazole, its (R) and (S) enantiomers, or pharmaceutically acceptable salts or esters thereof, and to methods of treatment which involve treating a subject with Ornidazole. The racemic (rac)-ornidazole, its enantiomers, or pharmaceutically acceptable salts or esters thereof, may be used in combination with other actives, and in particular, beta lactam antibiotics combined with beta lactamase inhibitors, like co-amoxiclay. The invention also relates to pharmaceutical formulations and compositions comprising (rac)-ornidazole, (R)-ornidazole, (S)-ornidazole, or pharmaceutically acceptable salts or esters thereof, and/or other actives and their use with bio-threat pathogens that utilize a mechanism of tolerance or resistance by facultatively switching from aerobic to anaerobic confirmations and by switching back and forth from planktonic to biofilm forms. | 2021-12-02 |
20210369676 | SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR TREATING SEIZURES AND CHRONIC INFLAMMATORY DISEASES - The invention disclosed herein relates to novel synergistic nutritional compositions for treating seizures and chronic inflammatory diseases. Particularly, the invention relates to potent and stable synergistic nutritional composition comprising combination of therapeutically active non-competitive amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPAR) antagonists and nuclear factor erythroid 2-related factor 2 (NRF2) activators, present in weight ratio of 1:0.001 to 1:0.5, along with pharmaceutically acceptable excipients. Further, the present synergistic nutritional composition is useful for treating conditions associated with seizure, fibrosis and diabetes. | 2021-12-02 |
20210369677 | SMALL MOLECULE ACTIVATORS OF POLYCYSTIN-2 (PKD2) AND USES THEREOF - Disclosed are methods of treating diseases or disorders associated with the activity of polycyctic kidney disease 2 (PKD2). The disclosed methods may be utilized to treat diseases or disorders associated with polycystic kidney disease, for example autosomal dominant polycystic kidney disease (ADPKD). Also disclosed are activators of PKD2. The disclosed compounds may also be used in pharmaceutical compositions and methods for treatment of polycystic kidney disease or disorders associated with PKD2 activity. | 2021-12-02 |
20210369678 | BENZIMIDAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS - Provided herein are methods of treating and preventing inflammatory bowel disease in a patient. The methods provided herein comprise administering to the patient in need thereof an effective amount of a benzoimidazole compound, Compound 1, to treat or prevent an inflammatory bowel disease in a patient. Also provided are formulations and routes of administration of the compound. | 2021-12-02 |
20210369679 | MEBENDAZOLE POLYMORPH FOR TREATMENT AND PREVENTION OF TUMORS - Mebendazole is an antiparasitic drug with over 40 years of safe use. Recently mebendazole was repurposed for glioblastoma therapy. Three polymorphs of mebendazole exist, but the relative polymorph content for existing drugs varies, and the therapeutic anti-cancer relevance of the different polymorphs was unknown. As an oral drug mebendazole polymorph C is a superior form, and it reaches the brain and brain tumors in effective concentrations. Efficacy is further improved by combining mebendazole with a P-glycoprotein inhibitor. Mebendazole may also be used for therapy of other cancers, as well as a chemo-preventative agent. | 2021-12-02 |
20210369680 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION - This disclosure describes the use of indane acetic acid derivatives which are PPAR agonists, including PPAR delta, PPAR gamma, and dual PPAR delta and gamma agonists, and which penetrate the blood brain barrier to achieve effective brain to plasma drug levels at non-toxic doses, for the treatment of betacoronavirus diseases, such as COVID-19 and COVID-19 related co-morbid diseases, including Acute Respiratory Distress and CNS disorders, such as delirium and cognitive impairment. | 2021-12-02 |
20210369681 | Identification of PPM1D mutations as a novel biomarker for NAMPTi sensitivity - The present invention provides a method of treating cancer in a subject, the method comprising administering to the subject at least one nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, thereby treating the cancer, wherein protein phosphatase Mg | 2021-12-02 |
20210369682 | [2-[(5-NITRO-1,3-THIAZOL-2-YL)CARBAMOYL]PHENYL]ETHANOATE FOR USE IN LYMPHANGIOLEIOMYOMATOSIS AND OTHER DISEASES - The present invention relates to the use of the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate in a method of treatment or prophylaxis of vascular and respiratory disease, fibrotic disease and neurodegenerative disease, particularly interstitial pneumonia, tuberous sclerosis or lymphangioleiomyomatosis, collagen disease, interstitial lung disease, human kidney disease, nephritic syndrome, liver fibrosis or liver cirrhosis, Alzheimer's disease or Parkinson's disease. | 2021-12-02 |
20210369683 | TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE - The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formula | 2021-12-02 |
20210369684 | RAPAMYCIN ANALOG FOR PREVENTION AND/OR TREATMENT OF NEURODEGNERATIVE CONDITIONS - This disclosure relates to a novel rapamycin analogue of Formula I or Formula II, mixtures, methods for its production, and its use in preventing and/or treating a neurodegenerative condition. | 2021-12-02 |
20210369685 | SUBSTITUTED AZACYCLES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the methods of preparation, pharmaceutical composition, combinations and the use of compound formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof. | 2021-12-02 |
20210369686 | OPHTHALMIC PREPARATIONS OF MUSCARINIC AGONIST AND METHODS OF USE - The present invention provides stable topical ophthalmic preparations of muscarinic agonist for the treatment of dry eye disease. The composition can include a polyunsaturated fatty acid. | 2021-12-02 |
20210369687 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE, AND LYSOSOMAL STORAGE DISORDERS - Provided herein are compositions and methods for treating or preventing a neurodegenerative disease, a myodegenerative disease, a prion disease or a lysosomal storage disease in a subject. | 2021-12-02 |
20210369688 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL - The present invention relates to compounds of Formula I, pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I increase significantly low density lipoprotein receptor and are useful for preventing and treating of elevated cholesterol. | 2021-12-02 |
20210369689 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP2C9 SUBSTRATES - Relacorilant is useful in the treatment of hypercortisolism and cancer. Many drugs useful in treating hypercortisolism or cancer are metabolized by CYP2C9 enzymes. The effects of concomitant administration of relacorilant and a CYP2C9 substrate are disclosed herein. | 2021-12-02 |
20210369690 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP2C8 SUBSTRATES - Relacorilant is useful in the treatment of cancer and hypercortisolism. Many drugs useful in treating cancer or hypercortisolism are metabolized by CYP2C8 enzymes. The effects of concomitant administration of relacorilant and a CYP2C8 substrate are disclosed herein. | 2021-12-02 |
20210369691 | METHODS AND COMPOSITIONS FOR IMPROVING BONE MARROW HEMATOPOIETIC FUNCTIONS - The present application provides methods and compositions for treating diseases related to hematopoietic dysfunction and/or injury, by attenuating the expression and/or function of SphK2. | 2021-12-02 |
20210369692 | IRON CHELATORS IN TUMOR THERAPY - The present invention relates to a pharmaceutically compatible iron chelator or a prodrug thereof for use in treating and/or preventing cancer in a subject suspected or known to comprise hypoxic cancer cells, and use in treatment and/or prevention of a human papillomavirus (HPV) related lesion. The present invention further relates to a use of an iron chelator or prodrug thereof for inducing senescence in a cancer cell, preferably a hypoxic cancer cell; and to a method for inducing an irreversible proliferation arrest in cancer cells comprising a) contacting said cancer cells with an iron chelator or prodrug thereof and, thereby, b) inducing an irreversible proliferation arrest in said cancer cells. | 2021-12-02 |
20210369693 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS - In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of pirfenidone. In some embodiments, the method comprises administering therapeutically effective amounts of pirfenidone and ubenimex as part of a combination therapy. | 2021-12-02 |
20210369694 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS - Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities. | 2021-12-02 |
20210369695 | PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRAN ETEXILATE AND PREPARATION METHOD THEREOF - Disclosed is a pharmaceutical composition containing dabigatran etexilate and a preparation method thereof. The pharmaceutical composition comprises a pharmaceutically active ingredient, dabigatran etexilate and/or dabigatran etexilate mesylate, and an polymer of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. The mass ratio of the two is 1:0.23 to 1:3. The pharmaceutical composition not only increases the bioavailability of the pharmaceutically active ingredient, but also reduces absorption variability, and provides a more stable concentration of dabigatran in plasma, thereby reducing adverse side effects. | 2021-12-02 |
20210369696 | Use of an N-substituted pyridyl benzisoselazolone compound - Disclosed is a use of an N-substituted pyridyl benzisoselazolone compound. The use is particularly a use in the preparation of a medicament for treating and/or preventing a disease caused by coronavirus. The present disclosure surprisingly found that the N-substituted pyridyl benzisoselazolone compound, such as ebselen, can significantly inhibit the activity of the main protease of a coronavirus and the intracellular replication capability of SARS-CoV-2, which can be used for treating a disease caused by coronavirus. | 2021-12-02 |
20210369697 | USE OF HEXOKINASE 2/MITOCHONDRIA-DETACHING COMPOUNDS FOR ACTIVATING IMMUNE RESPONSES - The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases. | 2021-12-02 |
20210369698 | Treating Dermatological Conditions with Chloroquine and/or Hydroxychloroquine - Embodiments of the invention involve treating skin afflictions by the topical or oral use of chloroquine and/or hydroxychloroquines. By effectively reducing or eliminating the population of | 2021-12-02 |
20210369699 | TREATMENT OF LUPUS ERYTHEMATOSUS USING S-HYDROXYCHLOROQUINE - A method for treating lupus erythematosus by administering to a patient a pharmaceutical composition that contains S-hydroxychloroquine (S-HCQ) and a pharmaceutically acceptable excipient. The pharmaceutical composition is essentially free of R-hydroxychloroquine (R-HCQ). The method is effective for treating cutaneous lupus erythematosus, systemic lupus erythematosus, and patients suffering from systemic lupus erythematosus that have concurrent lupus nephritis. Administration of S-HCQ in the claimed method has fewer side effects, particularly respecting cardiotoxicity, as compared to R-HCQ and to an equimolar mixture of S-HCQ and R-HCQ. | 2021-12-02 |
20210369700 | CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND PACLITAXEL, A DUAL SUBSTRATE OF CYP2C8 AND CYP3A4 - Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein. | 2021-12-02 |
20210369701 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators, including their use for treating amyotrophic lateral sclerosis (ALS). | 2021-12-02 |
20210369702 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE - The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase. | 2021-12-02 |
20210369703 | METHOD AND DEVICE OF TREATING CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS - The presently disclosed subject matter is directed to an effective method of treating chronic kidney disease-associated pruritus. Particularly, the method comprises the transmucosal administering of nalmefene to treat chronic kidney disease-associated pruritus, as well as cholestatic pruritus and/or prurigo nodularis. The nalmefene can be configured in a single layer film comprising at least two distinct domains. The film can include a first discrete domain comprising about 50-100 weight percent polymer matrix and the second discrete domain can comprise the nalmefene or pharmaceutically acceptable nalmefene salt. | 2021-12-02 |
20210369704 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING HEADACHE THROUGH ENHANCING 2-ARACHYDONYL GLYEROL ACTIVITY - This invention relates generally to compositions and methods for preventing, reducing the occurrence of or treating a headache in a subject in need thereof. In particular, the present invention relates to methods for enhancing 2-arachydonyl glycerol (2AG) tone and reducing prostaglandin activity in a subject for purposes of preventing, reducing the occurrence of or treating a headache (e.g., a migraine headache) in a subject. | 2021-12-02 |
20210369705 | COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS - The present invention relates to synergistic combinations of DNA-alkylating ADCs and ATR inhibitors. | 2021-12-02 |
20210369706 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF - The present invention is directed to compositions containing low-dose brimonidine and a second glaucoma drug. The present invention is further directed to methods of treating glaucoma by administering compositions of the present invention. | 2021-12-02 |
20210369707 | NOVEL USES - This invention relates to the new use of neurokinin-1 receptor antagonists as a treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs. Specifically, when the mechanical injury to the lungs is induced by mechanical ventilation or by the act of coughing in a subset of patients with pulmonary fibrosis conditions who cough. The invention further relates to pharmaceutical compositions comprising neurokinin-1 receptor antagonist drugs and to combinations for such uses. | 2021-12-02 |
20210369708 | COMPOSITION FOR PREVENTION OR TREATMENT OF MACULAR DEGENERATION - The present disclosure pertains to a pharmaceutical composition comprising fursultiamine or a salt thereof for prevention or treatment of macular degeneration. Fursultiamine decreases the upregulated expression of HIF-1α in retinal pigment epithelial cells and suppresses the growth of choroidal vascular endothelial cells. The pharmaceutical composition comprising fursultiamine or salts thereof according to the present disclosure can be used as a therapeutic agent for various neovascular ocular diseases. | 2021-12-02 |
20210369709 | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER - The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). | 2021-12-02 |
20210369710 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN - Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions. | 2021-12-02 |
20210369711 | USES OF COMPOUND IN PREPARATION OF DRUGS FOR TREATING BRAIN GLIOMA - The present invention provides uses of a compound represented by formula A in the preparation of drugs for treating brain glioma and particularly glioblastoma. Particularly provided are uses of the compound represented by formula A in the preparation of drugs for treating expression of specific fusion protein. By means of the technical solution of the present invention, typing of brain glioblastoma can be implemented, a drug administration can be carried out for a specific patient group, and precise treatment can be implemented. | 2021-12-02 |
20210369712 | MULTIKINASE INHIBITORS AND USES IN REPRODUCTIVE AND DIGESTIVE TRACT FIBROSIS - A method for preventing and/or treating fibrosis associated with a reproductive tract or digestive tract disease or disorder includes administering an effective amount of a multikinase inhibitor to an animal or human in need thereof. The multikinase inhibitor comprises axitinib, nintedanib, sunitinib, lenvatinib, regorafenib, ponatinib, pazopanib, riociguat, or a salt thereof. The reproductive tract or digestive tract disease or disorder comprises uterine fibroids or primary sclerosing cholangitis, including Intra uterine surgery, intra uterine synechiae, Asherman's syndrome, biliary duct fibrosis, biliary duct sclerosis, and primary biliary cirrhosis. | 2021-12-02 |
20210369713 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS - In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2021-12-02 |
20210369714 | Prevention and Treatment of Osteoarthritis by Inhibition of Insulin Growth Factor-1 Signaling - The present disclosure provides methods for treating or preventing osteoarthritis in a subject in need thereof. In certain aspects, the methods include administering an inhibitor of insulin growth factor-1 (IGF-1) signaling to a joint of the subject in an amount effective to treat or prevent osteoarthritis. In certain aspects, the osteoarthritis treated or prevented by the methods disclosed herein may to be post-traumatic osteoarthritis. | 2021-12-02 |
20210369715 | NOVEL USES - The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein. | 2021-12-02 |
20210369716 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES - The present invention provides compounds of Formula A: | 2021-12-02 |
20210369717 | LIQUID ORAL FORMULATIONS FOR PDE V INHIBITORS - The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc. | 2021-12-02 |
20210369718 | COMPOSITIONS FOR MENTAL ALERTNESS AND METHODS OF MAKING AND USING THEREOF - The application provides nutraceutical compositions supporting mental alertness. In one embodiment, the nutraceutical composition comprises an active component and a gelling component in a sufficient amount to provide a cohesive gelled product. The active component comprises a carbohydrate composition, a vitamin B composition, a caffeinated composition and an anxiolytic composition, wherein the carbohydrate composition comprises a high glycemic index (GI) sugar having a GI not less than 70. | 2021-12-02 |
20210369719 | Accelerated Treatment of COVID-19 and SAR's Type Viruses - The present invention provides a solution mixture of 1.8 to 3.7% hypertonic saline, 70 to 85% ethanol as solvent alternating with 10 milliliters 50 to 90% of 75 to 110 mg theobromine in a nebulized aerosol for inhalation by COVID-19 and SARS patients. Alternatively, theobromine may be infused alternating with inhaled nebulized exogenous pulmonary surfactant as replacement. For advanced COVID-19, SARS patients, the inhalation described above may be alternated with an intravenous solution of 1.8% to 2.2% hypertonic solution of theobromine as 450 mg to 650 mg in ethanol, twice daily. | 2021-12-02 |
20210369720 | SYNERGISTIC COMPOSITION HAVING NEUROPROTECTIVE PROPERTIES AND METHODS OF USE THEREOF - A neuroprotective compositions containing caffeine or a caffeine analogue and a long chain fatty acyl tryptamide with an aliphatic chain having 16 to 22 carbons linked to a tryptamine, wherein the composition contains from at least 1.5 mg to 600 mg of caffeine per serving or unit dosage of the composition; from at least 0.5 mg to 300 mg of the long chain fatty acyl tryptamide per serving or unit dosage of the composition; and the ratio of long chain fatty acyl tryptamide to caffeine is from 1:1200 to 200:1. Methods are also disclosed for treating or preventing cognitive and movement deficits of a disease, condition or disorder or neurological deterioration that use the disclosed neuroprotective compositions. | 2021-12-02 |
20210369721 | SUBLINGUAL FORMULATION FOR HYPOTENSION AND SYNCOPE - The present invention relates to composition, formulations and devices for preventing vasovagal syncope attack, and in particular to the use of combinations of capsaicin, caffeine, and/or α-agonists to prevent syncope. | 2021-12-02 |
20210369722 | USE OF REBOXETINE TO TREAT NARCOLEPSY - Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being. | 2021-12-02 |
20210369723 | Purine derivatives and the use thereof as medicament - The present invention relates to novel purines of general formula A | 2021-12-02 |
20210369724 | COMBINATION OF ATR KINASE INHIBITORS WITH 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE COMPOUNDS - The present invention relates to combinations of: component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2) as defined herein, or a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof; and component B: one or more ATR kinase inhibitor(s) as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof; and, optionally, component C: one or more further pharmaceutical agent(s); and, optionally, in which either or both of components A and B in any of the above-mentioned combinations are in the form of a pharmaceutical composition which is ready for use to be administered simultaneously, concurrently, separately or sequentially. The components may be administered independently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route. | 2021-12-02 |
20210369725 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION - The invention concerns compositions and a method for treating or delaying the onset, progression, or relapse of a cancer in a subject, the method comprising administering, optionally with radiation therapy, an inhibitor of: (a) DNA-Dependent Protein Kinase catalytic subunit, and an inhibitor of Poly-ADP Ribose Polymerase, wherein the cancer has a histone H3.3 mutation or is a homologous recombination-defective (HR-defective) cancer; or (b) wild-type isocitrate dehydrogenase, wherein the IDH inhibitor is administered in an effective amount to decrease wild-type IDH activity in cells of the cancer, and wherein the cancer carries a histone H3.3 K27M mutation, and/or the cancer has low DNA methylation and/or low histone methylation; or (c) histone acetyltransferase, wherein the cancer carries a histone H3.3 K27M mutation, and/or high histone acetylation; or (d) histone deacetylase, wherein the cancer carries a histone H3.3 K27M mutation, and/or has high histone acetylation; or (e) any combination thereof. | 2021-12-02 |
20210369726 | OPHTHALMIC COMPOSITIONS OF RIFAMYCINS AND USES THEREOF - Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations. | 2021-12-02 |
20210369727 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES - A novel compound able to inhibit JAK is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6. | 2021-12-02 |
20210369728 | OPHTHALMIC COMPOSITION OF BRINZOLAMIDE AND BRIMONIDINE - The present invention relates to an ophthalmic composition comprising brinzolamide or pharmaceutically acceptable salts thereof, and brimonidine or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. It further relates to a method of preparing such compositions and their use for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. | 2021-12-02 |
20210369729 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T | 2021-12-02 |
20210369730 | ANTIVIRAL TREATMENT - A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 μg per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant. | 2021-12-02 |
20210369731 | COVALENT TARGETING OF E3 LIGASES - Disclosed herein, inter alia, are compositions and methods for targeting E3 ligases. In an aspect is a targeted protein degrader including 1) a targeted protein binder and 2) an E3 Ubiquitin ligase binder, wherein the E3 Ubiquitin ligase is human RNF4 or human RNF114. In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient. | 2021-12-02 |
20210369732 | PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl- )PHENYL]ETHYL}-1,4-OXAZEPANE-2-CARBOXAMIDE - The present disclosure relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof. | 2021-12-02 |
20210369733 | BETULIN-CONTAINING BIRCH BARK EXTRACTS AND THEIR FORMULATION - The present disclosure relates to birch bark extracts, methods of producing such extracts, stable pharmaceutical compositions containing such extracts and methods of using of such extracts. The birch bark extracts of the present disclosure contain triterpenes, which are known to improve wound healing. | 2021-12-02 |
20210369734 | COMPOUNDS AND METHODS OF THEIR USE - Compounds, compositions, and methods for treating injuries caused by exposure to chemical warfare and similar agents are described herein. | 2021-12-02 |
20210369735 | PHYTOECDYSONES FOR USE IN THE PREVENTION OF MUSCLE STRENGTH LOSS DURING IMMOBILISATION - A composition including at least one phytoecdysone or at least one semi-synthetic derivative of a phytoecdysone, for use in mammals for preventing the loss of muscle strength during immobilisation. More particularly, a composition for use that includes 20-hydroxyecdysone or a semi-synthetic derivative of 20-hydroxyecdysone. Moreover, the composition for use includes a compound of general formula (I). | 2021-12-02 |
20210369736 | COMPOSITION FOR PREVENTION OR TREATMENT OF ALLERGIC DISEASE INCLUDING INOTODIOL COMPOUND AS ACTIVE INGREDIENT - Provided is a composition for prevention or treatment of an allergic disease, the composition including an inotodiol compound and a chaga mushroom ( | 2021-12-02 |
20210369737 | PROSTATE FUNCTION SUPPORT FORMULA - The invention provides unit dosage forms and methods that are effective to improve prostate function. Such unit dosage forms and methods are useful to decrease bladder discomfort and improve urinary flow in men. | 2021-12-02 |
20210369738 | PRODUCTION METHOD OF TELOMERASE ACTIVATORS AND TELOMERASE ACTIVATORS OBTAINED BY THIS METHOD - A method for producing telomerase activators which provide to obtain new/novel molecules (metabolites) from saponin group compounds by using biotransformation with endophytic fungi and telomerase activators obtained by this method. Included is the elucidation of chemical structures and investigation of the effects of telomerase enzyme activation in cells. These molecules have the potential to be used in diseases and/or conditions that can be treated/ameliorated by telomerase activation and associated with telomere shortening (For example; HIV, degenerative diseases, acute and chronic wound healing, ex vivo cell therapies and stem cell proliferation due to increment in vitro and ex-vivo replicative capacity of cells). | 2021-12-02 |
20210369739 | COMBINATION THERAPY OF ACYLTHIOUREA COMPOUND AND ABIRATERONE - Combination therapy of cancer using a c-Met selective inhibitor, an acylthiourea compound or a pharmaceutically acceptable salt thereof, and showing an excellent antitumor effect with less side effects is provided. An antitumor agent contains a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: | 2021-12-02 |
20210369740 | Synthesis of Anti-inflammatory and Anti-cancer Agents through Fungal Transformation of Mibolerone - Four new analogues, 17β-hydroxy-7α,17α-dimethylestr-4,6-diene-3-one (2), 11β,17β-dihydroxy-7α, 17α-dimethyl-estra-1,3,5-triene-3-one (3), 3α,10β,17β-trihydroxy-7α,17α-dimethyl-5α-estrane (4), and 17β-hydroxy-7α,17α-dimethyl-5α-estrane-3,6-dione (5) of anabolic drug mibolerone (1) were synthesized. Derivatives 2 (IC | 2021-12-02 |
20210369741 | VITAMIN D AS AN IMMUNE MODULATOR TO PREVENT IMMUNE-RELATED COMPLICATION FROM COVID-19 INFECTION - Disclosed herein are methods and compositions useful in reducing inflammation, reducing inflammatory exudates, enhancing epithelial tissue generation or regeneration, and/or reducing mean pulmonary artery pressure in the lungs of a subject in need thereof. In particular, the compositions comprise vitamin D, an analog, or metabolite thereof, and the methods include administering the composition to a subject in need thereof. In some embodiments, the subject is suffering from an infection, such as a viral infection, which affects the lungs. In some embodiments, the viral infection comprises SARS-CoV-2. | 2021-12-02 |
20210369742 | METHODS OF TREATING THROMBOSIS - The present invention provides in certain embodiments methods of inhibiting platelet function or thrombosis, inhibiting pyruvate kinase M2 (PKM2) dimerization, and/or treating a disease associated with thrombosis by administering a composition comprising a dimeric pyruvate kinase M2 (PKM2) inhibitor in a patient in need thereof. | 2021-12-02 |
20210369743 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING SULFASALAZINE AND/OR A SULFASALAZINE ORGANINC SALT, PRODUCTION PROCESS AND USE - Disclosed is to a new pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production processes and uses, in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and/or the gastro-intestinal tract. | 2021-12-02 |
20210369744 | COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION - The present disclosure provides a conjugate comprising an affinity agent, a branched linker, and two or more photoisomerizable regulators. The present disclosure provides compositions comprising the conjugate, as well as devices comprising the compositions. The present disclosure provides methods for enhancing visual function, the methods comprising administering the conjugate to an individual in need thereof. | 2021-12-02 |
20210369745 | DRINK PRODUCT AND USE THEREOF - A drink product having pharmaceutical compositions as an active ingredients of, at least one phosphorylated inositol, optionally Genistein, optionally Ubiquinol, and optionally additional unphosphorylated inositol. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed. | 2021-12-02 |
20210369746 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS IN COMBINATION WITH IMMUNE MODULATORY AGENTS FOR TREATING CANCER - Cancer can be treated by administration of TH-302 in combination with an immunomodulator. | 2021-12-02 |
20210369747 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer - Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both. | 2021-12-02 |
20210369748 | COMBINATION THERAPY FOR CANCER TREATMENT - The present disclosure relates to methods for treating cancer, or preventing cancer recurrence or progression, comprising administering a patient an anti-CD38 antibody and a proteasome inhibitor. | 2021-12-02 |
20210369749 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY - The present disclosure features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of compounds disclosed herein. | 2021-12-02 |
20210369750 | NICOTINAMIDE RIBOSIDE COMPOSITIONS FOR HEALTHSPAN EXTENSION - Described herein are methods and compositions comprising nicotinamide riboside and alpha-ketoglutarate for treating frailty, for maintaining health, and for re-growing hair. | 2021-12-02 |
20210369751 | BIOLOGICALLY ACTIVE COMPOSITIONS AND METHODS OF USING - Disclosed herein is a composition comprising a biologically active amount of nicotinamide mononucleotide or a derivative thereof, apigenin or a derivative thereof, quercetin or a derivative thereof, and bioperine or a derivative thereof. A method of treating a physiological condition using the composition is also disclosed. | 2021-12-02 |
20210369752 | SYSTEMS FOR TREATING PULMONARY INFECTIONS - Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a | 2021-12-02 |
20210369753 | NUTRIENT COMPOSITION ABLE TO INHIBIT QUORUM SENSING - Described, among other things, are dosage forms for administration to a subject, the dosage forms having at least six ingredients are selected are from the group consisting of clove powder, rutin, hesperidin, baicalin, sulforaphane, moringa leaf extract, rosmarinic acid, guava leaf extract, | 2021-12-02 |
20210369754 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA - Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, preventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus. | 2021-12-02 |
20210369755 | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication - Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, | 2021-12-02 |
20210369756 | USE OF CYCLIC ADENOSINE MONOPHOSPHATE, DERIVATIVE OR PRODRUG THEREOF IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING DEPRESSION - The disclosure discloses a use of cyclic adenosine monophosphate (cAMP), derivative or prodrug thereof in preparation of drug for preventing and/or treating depression. Using the established model of depressed mice caused by social defeat stress, cAMP is intraperitoneally injected upon constructing the model or directly injected into the nucleus accumbens brain region of depressed mice after modeling, which can significantly improve the depression-like behavior of mice. The disclosure discloses the prevention and treatment effect of cAMP on depression, and provides a candidate drug with new mechanism for clinical prevention and treatment of depression. | 2021-12-02 |
20210369757 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS - The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof. | 2021-12-02 |
20210369758 | DOUBLE-STRANDED OLIGO RNA STRUCTURE COMPRISING miRNA - The present invention relates to a double-stranded oligo RNA structure comprising double-stranded miRNA, and a composition for preventing or treating cancer, containing the same. More specifically, the present invention relates to an anti-cancer pharmaceutical composition, containing: a double-stranded oligo RNA structure comprising miR-3670, miR-4477a and miR-8078, and characterized by a method for effectively inhibiting cancer cell proliferation or inducing cancer cell apoptosis; and a pharmaceutically acceptable carrier. | 2021-12-02 |
20210369759 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID EXPRESSION INVOLVING INHIBITION of NF-kB PATHWAYS AND/OR IRF PATHWAYS - Nucleic acid expression systems for delivery of oligonucleotides, such as RNA oligonucleotides, to target cells and methods of using the same are provided herein. Exemplary nucleic acid expression systems for expression of a payload sequence include at least one composition that delivers an inhibitor of a NF-κB pathway and/or an inhibitor of an IRF pathway. Provided herein are also pharmaceutical compositions that deliver an inhibitor of a NF-κB pathway and/or an inhibitor of an IRF pathway, and methods of using the same for enhancing expression of an oligonucleotide, such as an RNA oligonucleotide. | 2021-12-02 |
20210369760 | MICRORNA-BASED THERAPY TARGETED AGAINST LCP-1 POSITIVE CANCERS - The present invention relates to a panel of miRNAs comprising miR-16-5p, miR-23a-5p, miR-125b-5p, miR-145-5p, miR-146a-3p, miR-181c-5p, miR-218-5p, miR-495-3p, let-7b-5p, and further comprising one or more miRNAs selected from the group consisting of miR-30a-5p, miR-30b-5p, miR-30c-5p, miR-30d-5p, miR-30e-5p, miR-194-5p, miR-302a-3p, miR-302a-5p, miR-335-3p, miR-335-5p, miR-367-3p, miR-373-3p, and miR-885-5p, and to extracellular vesicles (EVs), e.g. of stem cell origin, loaded with the panel of miRNAs. The present invention further provides the panel or EVs for use in a method of treating LCP-1 positive cancer in a patient. | 2021-12-02 |
20210369761 | METHODS OF TREATING MOTOR NEURON DISEASES - A method of treating a subject having MND is provided. The method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of miR-218, miR-218*, precursor thereof and a polynucleotide sequence encoding miR-218 or miR-218* or precursor thereof, thereby treating the MND in the subject. A method of treating a subject having MND, the method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating an activity or expression of a gene product selected from the group consisting of KCND2, KCNH1, GABRB2, SLC6A1, SLC6A11, KCNA1, CACNB4, GRIA2, GRIK2, GABRG1 and GRIK3, is also provided. | 2021-12-02 |
20210369762 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY - Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy. | 2021-12-02 |
20210369763 | TREATMENT OR PREVENTION OF ANAEMIA IN PREGNANT NON-HUMAN MAMMALS - The present invention relates to an iron carbohydrate complex for use in a method of increasing the blood haemoglobin concentration in a pregnant non-human mammal, wherein the pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, is administered one or more doses of iron carbohydrate complex comprising an amount of elemental iron of 1800 mg or more per dose. The method relates to the further effects of decreasing the rate of stillborn offsprings from a pregnant non-human mammal having a blood haemoglobin level of 105 g/L or less, increasing the blood haemoglobin concentration of offspring litters within 3 days from birth and/or weaning, or increasing the litter size in a subsequent parity of a non-human mammal having a blood haemoglobin level of 105 g/L or less. | 2021-12-02 |
20210369764 | HYALURONIC ACID FOR RELIEF OF IDIOPATHIC OCULAR PAIN - The invention concerns a method for relieving idiopathic ocular pain by administering an effective amount of a fluid composition comprising hyaluronic acid, a hyaluronic acid analogue, or a combination thereof, to the eye of a human or non-human animal subject, wherein the fluid composition is administered after onset of the idiopathic ocular pain and in the absence of detectable signs known to cause ocular pain. | 2021-12-02 |
20210369765 | USE OF AGAR-DERIVED OLIGOSACCHARIDES FOR INHIBITING GROWTH OF STAPHYLOCOCCUS - The present invention relates to a use of agar-derived oligosaccharides for inhibiting the growth of | 2021-12-02 |